Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 20;22:207. doi: 10.1186/s12916-024-03420-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 5 — MRI images and TCR clonotypes in the representative patients. Patient ID 01 had progressive metastases of cervical cancer in the bladder followed by a complete response to TILs. A The sum of radiographic target lesions is shown over time with representative contrast-enhanced axial MRI images in patient ID 01. B Changes in T cell clonotypes and lymphocytes in peripheral blood after infusion. C Changes in exogenous and endogenous TCR clonotypes within 30 days after TIL infusion. D MRI images of target lesions during the follow-up. Patient ID 07 had progressive metastases of endometrial cancer in the anterior wall of the rectum followed by a complete response to TILs. E The sum of radiographic target lesions. F Changes in T cell clonotypes and lymphocytes. G Changes in exogenous and endogenous TCR clonotypes within 30 days after TIL infusion. H MRI images of target lesions during the follow-up. Patient ID 04 had progressive metastases of cervical cancer in the bladder followed by a partial response to TILs. I Sum of radiographic target lesions. J Changes in T cell clonotypes and lymphocytes. K Changes in exogenous and endogenous TCR clonotypes within 30 days after TIL infusion. L MRI images of target lesions during the follow-up